DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma
Erika Hamilton
Cancer Treatment Reviews
The evolving landscape of antibody-drug conjugates in gynecologic cancers
ASCO Education Book
Rise of Antibody-Drug Conjugates: The Present and Future
Cancer
Phase 1b study of pan-AKT inhibitor vevorisertib alone or with paclitaxel or fulvestrant in PIK3CA/AKT/PTEN-mutated advanced solid tumors
Clinical Advances in Hematology & Oncology
Novel endocrine therapy agents in ER-positive, HER2-negative breast cancer
The Lancet
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
Nature Reviews. Drug Discovery
Targeting HER2-positive breast cancer: advances and future directions